Cargando…
Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
ALK rearrangements have been observed in 0.05%–2.5% of patients with colorectal cancers (CRCs) and are predicted to be oncogenic drivers largely mutually exclusive of KRAS, NRAS, or BRAF alterations. Here we present the case of a patient with metastatic CRC who was treatment naïve at the time of mol...
Autores principales: | Lai, Andrea Z., Schrock, Alexa B., Erlich, Rachel L., Ross, Jeffrey S., Miller, Vincent A., Yakirevich, Evgeny, Ali, Siraj M., Braiteh, Fadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507649/ https://www.ncbi.nlm.nih.gov/pubmed/28507204 http://dx.doi.org/10.1634/theoncologist.2016-0376 |
Ejemplares similares
-
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022) -
A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
por: Wang, Victoria E., et al.
Publicado: (2017) -
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu, Viola W, et al.
Publicado: (2018) -
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock, Alexa B, et al.
Publicado: (2020) -
4267 Noninvasive hybrid ultrasound and photoacoustic imaging for the assessment of liver fibrosis
por: Sultan, Laith Riyadh, et al.
Publicado: (2020)